Boston Scientific showcases potential of its new catheter
On 3/17/2019, Boston Scientific announced positive results from the AF-FICIENT I study that evaluated the safety and efficacy of its LUMINIZE‚Ñ¢ Radiofrequency (RF) Balloon Catheter. This recently acquired single-shot ablation technology is designed to isolate the pulmonary veins (PV) when treating patients with atrial fibrillation (AF). The device identifies the areas of the heart muscle that are responsible for abnormal heart rhythms using RF energy. Meanwhile, Boston Scientific continues to innovate in the space of cardiac health, including a patent application assigned to one of its subsidiaries, Cardiac Pacemakers, that details directly measuring heart sounds using mobile device accelerometers.
Related Posts
Cala Health Claims to Have the only Patented Neurostimulation for Essential Tremor Treatment. The Patent Data Disagrees
Cala Health has figured out that innovations backed by patents make them exponentially more valuable in the marketplace. However, in a zest…
Capital One is Investing in AI Biotech? What’s in their wallet?
In the past 18 months, Capital One has expanded past its usual banking activities, and begun exploring the AI Biotech Sector. But do they…
Google AI Reinvents Speech Recognition. Who will follow?
There is no doubt that the big 5 tech companies (Apple, Amazon, Google, Facebook, and Microsoft) have developed massive IP portfolios in…